Prudential Financial
ELVN icon

Prudential Financial’s Enliven Therapeutics ELVN Stock Holding History

Prudential Financial’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$892K Sell
17,580
-49,360
-74% -$2.1M ﹤0.01% 1691
2026
Q1 		$2.62M Buy
66,940
+31,360
+88% +$869K ﹤0.01% 1204
2025
Q4 		$548K Buy
+35,580
New +$709K ﹤0.01% 1806

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Prudential Financial's ELVN Position: Q2 2026 in Review

Prudential Financial reduced its Enliven Therapeutics (ELVN) stake by 74% in Q2 2026, selling an estimated $2.1M and leaving 17,580 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

Prudential Financial first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.62M in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Prudential Financial held 17,580 shares of Enliven Therapeutics worth $892K as of Q2 2026.
  • Prudential Financial sold 49,360 Enliven Therapeutics shares in Q2 2026, an estimated $2.1M.
  • Enliven Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1691 holding.
  • Prudential Financial first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Prudential Financial's Enliven Therapeutics position peaked at $2.62M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.